Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node

Annals of Surgical Oncology

Volumn 6, Issue 1, 1999, Pages 95-101

  Schreiber, Robert H ^a   Pendas, Solange ^d   Ku, Ni Ni ^b   Reinigen, Douglas S ^a   Shons, Alan R ^a   Berman, Claudia ^a   Boulware, David ^c   Cox, Charles E ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Cytokeratin; Microstaging; Sentinel lymph nodes

Indexed keywords

CYTOKERATIN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER PATIENT; CANCER STAGING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PROGNOSIS; TUMOR VOLUME;

BIOPSY, NEEDLE; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; KERATINS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; TECHNETIUM TC 99M SULFUR COLLOID;

EID: 0033061344     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0095-3     Document Type: Article

References (25)

1. Cox CE, Pendas S, Cox JE, Reintgen DS, et al. Guidelines for sentinel node biopsy and lymphatic mapping of breast cancer patients. Ann Surg 1998;227(5):645-53.
2. Cox CE, Bass SS, Ku NN, Berman C, Shons A, Yeatman T, Reintgen D. Sentinel lymphadenectomy: a safe answer to less axillary surgery. In the Proceedings of the 6th International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen, Switzerland, February 25-28, 1998.
3. Dowlatshahi K, Fan M, Snider HC. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997; 80(7):1188-97.
4. Gershenwald JE, Colomi MI, Thompson W, et al. Multiinstitutional melanoma lymphatic mapping experience: problems of failure in 423 stage I & II melanoma patients after successful lymphatic mapping and negative SLN biopsy. J Clin Oncol (in press).
5. Redding WH, Coombes RC. Detection of micrometastases in patients with primary breast cancer. Lancet 1983;2:1271-4.
6. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-8.
7. Shoenfeld A, Lugamani Y, Smith D, et al. Detection of breast cancer micro-metastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 1994;54:2986-90.
8. Noguchi S, Aihara T, Motomura K, et al. Detection of breast cancer micro-metastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Am J Pathol 1996;2:649-56.
9. Noguchi S, Aihara T, Motomura K, et al. Histologic characteristics of breast cancers with occult lymph node metastases detected by keratin 19 mRNA reverse transcriptase-polymerase chain reaction. Cancer 1996;78:1235-40.
10. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathological validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-6.
11. Albertini JJ, Lyman GH, Cox CE, Reintgen DS, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
12. Cox CE, Ku NN, Reintgen DS, et al. Touch preparation cytology of breast lumpectomy margins with histologic correlation. Arch Surg 1991;126:490-3.
13. Ku NK, Ahmad N, Smith PV, Cox CE, Reintgen DS, Nicosia SV. Intraoperative imprint cytology of sentinel lymph nodes in breast cancer. Acta Cytol 1997;41(5):1606-7.
14. Anderson BO, Austin-Seymour M, Gralow J, Moe RR, Byrd DR. A multidisciplinary approach to locoregional management of the axilla for primary operable breast cancer. Cancer Control 1997J; 14(6):491-499.
15. Copeland EM III. Is axillary dissection necessary for T1 carcinoma of the breast? J Am Coll Surg 1997;184(4):397-8.
16. Ruffin WK, Stacey-Clear A, Younger J, Hoover HC. Rational for routine axillary dissection in carcinoma of the breast. J Am Coll Surg 1995;180:245-51.
17. Giuliano AE, Dale PS, Turner RR, Morton DL, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394-99.
18. Graversen HP, Blichert-Toft M, Andersen JA, Zedeler K. Breast cancer: risk of axillary recurrence in node negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988;14:407-12.
19. Cady B. Is axillary lymph node dissection necessary in routine management of breast cancer? No. Important Adv Oncol 1996:251-65.
20. Haffty BG, Ward B, Pathare P. Reappraisal of the role of axillary lymph node dissection in conservative treatment of breast cancer. J Clin Oncol 1997;15(2):691-700.
21. Veronesi U, Paganelli G, Galimberti V, Viale G, et al. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 1997;349:1864-7.
22. Noguchi M. Node negative breast cancer patients exposed to unnecessary perioperative risk and increased long-term morbidity (letter). Ann Surg 1997;225:126-36.
23. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-8.
24. Giuliano AE. Lymphatic mapping and sentinel node biopsy in breast cancer (letter). JAMA 1997;277:791-2.
25. Giuliano AE, Jones RC, Brennan M, Statman RR. Sentinel lymph-adenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.